本次活动中，京东健康联合腾讯广告、快手磁力引擎、微博、巨量引擎、网易云音乐、B站、知乎等多 个渠道共同启动品牌全域增长计划，共同整合了京东健康站内外的资源优势，通过全域数字化营销，为 品牌合作伙伴提供全方位的支持，来满足用户个性化、多样化的医药消费新需求。 8月18日，以"精准营销赋能，通向高效增长"为主题的2025西普会——京东健康特约专场在海南博鳌举 行。与会嘉宾共同探讨在面对市场多重挑战下，如何通过精准营销实现健康产业的高效增长。 北京同仁堂数字科技有限公司总经理孙恺分享了如何通过与京东健康合作开展年轻化营销，实现老字号 的营销变革。今年京东为北京同仁堂京东超级品牌日营销定制解决方案，一站式覆盖超品传播全周期 品、效、销全媒介链路打通，最终实现超过23亿的曝光，活动爆发期28小时内，北京同仁堂产品销售同 比增长超7倍、用户点击同比增长超3倍；重点品类销售成绩亮眼，妇科用药、补益类用药和中风用药均 登顶行业销量TOP1。 孙恺认为，在数字化的时代，京东健康的精细化运营可以更好地帮助品牌精准触达目标用户，结合北京 同仁堂在中医药行业的产品研发优势和专家资源，为消费者提供更专业更值得信赖的品牌和产品服务， 提 ...

Group 1 - The core viewpoint of the report is that Sanofi Bio's performance meets expectations, with a stable market position and potential for accelerated growth in Continuous Glucose Monitoring (CGM) products [1][2][3] - In 2024, the company is projected to achieve revenue of 4.443 billion yuan, a year-on-year increase of 9.47%, and a net profit of 326 million yuan, up 14.73% [1] - The company holds nearly 50% market share in the retail blood glucose product market, with over 22 million users and partnerships with more than 4,000 distributors and nearly 600 chain pharmacies [1] Group 2 - The company is advancing its international strategy, with a seven-year distribution agreement signed with A.MENARINI DIAGNOSTICS covering over 20 countries and regions [2] - The CGM product has entered a critical review phase after passing FDA 510(k) acceptance [2] - The second-generation CGM product has received Class III NMPA registration, featuring improved accuracy and stability compared to the first generation, with a monitoring error rate (MARD) of 8.71% [3] Group 3 - Revenue forecasts for 2025-2027 are 4.887 billion, 5.572 billion, and 6.129 billion yuan, with corresponding EPS of 0.71, 0.94, and 1.14 yuan [4] - The current stock price corresponds to a PE ratio of 30.9, 23.4, and 19.2 for the years 2025, 2026, and 2027 respectively [4] - The company is expected to see significant growth in the US market following CGM product approvals [4]

4月8日至11日，第91届中国国际医疗器械（春季）博览会（以下简称"CMEF"）在国家会展中心（上 海）举办。本届展会旨在展示全球医疗器械领域的最新成果，洞察健康科技的前沿趋势，持续重构商贸 价值链，助推医疗器械全产业链高质量发展。展会上，京东健康与鱼跃、欧姆龙、三诺、瑞迈特、可 孚、稳健医疗、振德医疗、英科医疗、墨尼克医疗、联影十大品牌签约，多个品牌宣布其年度重磅新品 将在京东健康全网首发，为行业高质量发展注入新动能。 全 面升级品牌战略合作：深度融合供应链优势、服务闭环及技术创新 展会期间，京东集团SEC委员、京东健康CEO金恩林与鱼跃医疗董事长吴群签署战略合作协议，2025 年，京东健康将与鱼跃重磅合作安耐糖5代动态血糖仪新品，共同打造糖尿病管理平台。双方将深度融 合"京医千询"医疗大模型与鱼跃智能监测设备数据、三甲医生在线问诊、精准用药指导的闭环服务体 系，并生成千人千面的智能干预方案，重构动态血糖仪（CGM）"极速配送-AI辅助干预-护士到家服 务"全场景服务闭环，共同实现从单点商品交付到全周期健康管理的数智化跃迁，预计覆盖超500万糖尿 病患者家庭，重塑糖尿病管理服务标准。 精准升级，京东健康与欧 ...